Clinical Pharmacogenomics: Opportunities and Challenges at Point of Care

One of the major barriers to implementing clinical pharmacogenomics has been the efficient integration of rapid turnaround-time genetic testing into routine clinical practice. To address this specific challenge, both point-of-care and preemptive pharmacogenomic testing programs, initially centered on cardiovascular pharmacogenomics, have recently been deployed. Early results indicate that these strategies are feasible and probably beneficial clinically; however, despite these exciting advances toward implementing clinical pharmacogenomics, challenges to widespread adoption remain. Clinical Pharmacology & Therapeutics (2013); 93 1, 33–35. doi:10.1038/clpt.2012.196